DUBLIN--(BUSINESS WIRE)--The "2018 Cell Surface Markers: US, Europe, Japan - Competitive Strategies, Country Forecasts, Innovative Technologies, Emerging Opportunities" report has been added to ResearchAndMarkets.com's offering.
The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells. A synergistic combination of the hybridoma technology with flow cytometry is further expanding the applications of both technologies.
During the next five years, the main trend in cell surface marker analysis will be further simplification of the sample preparation and the analysis itself.
This report presents a detailed overview of the CD4, CD8 and CD34 Cell Surface Marker testing in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5-year test volume forecasts by country and market segment.
The report examines market applications of monoclonal antibodies, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.
Companies Featured
- Abbott
- Agilent Technologies
- Beckman Coulter/Danaher
- Becton Dickinson
- Bio-Rad
- CellaVision
- Horiba
- Nihon Kohden
- Ortho-Clinical Diagnostics
- Roche
- Siemens Healthineers
- Sysmex
For more information about this report visit https://www.researchandmarkets.com/research/2wch9v/2018_cell_surface?w=4
